Longeveron Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 38

Employees

  • Stock Symbol
  • LGVN

Stock Symbol

  • Share Price
  • $1.66
  • (As of Friday Closing)

Longeveron General Information

Description

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Life Science & Technology Park, 1951 North West 7th Avenue
  • Suite 520
  • Miami, FL 33136
  • United States
+1 (844)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • Life Science & Technology Park, 1951 North West 7th Avenue
  • Suite 520
  • Miami, FL 33136
  • United States
+1 (844)

Longeveron Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Longeveron Stock Performance

As of 20-Nov-2026, Longeveron’s stock price is $1.66. Its current market cap is $5.6M with 3.37M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.66 $1.82 $1.31 - $12.30 $5.6M 3.37M 115K -$7.95

Longeveron Financials Summary

As of 30-Sep-2026, Longeveron has a trailing 12-month revenue of $1.17M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (920) 2,533 4,489 32,398
Revenue 1,165 1,199 2,392 709
EBITDA (21,411) (21,478) (15,015) (20,467)
Net Income (22,388) (22,704) (15,973) (21,413)
Total Assets 12,015 10,261 25,558 12,078
Total Debt 412 824 1,447 2,041
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Longeveron Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Longeveron‘s full profile, request access.

Request a free trial

Longeveron Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical need
Drug Discovery
Miami, FL
38 As of 2025

Basking Ridge, NJ
 

Houston, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Longeveron Competitors (9)

One of Longeveron’s 9 competitors is Lisata Therapeutics, a Corporation company based in Basking Ridge, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lisata Therapeutics Corporation Basking Ridge, NJ
Coya Therapeutics Formerly VC-backed Houston, TX
Cynata Therapeutics Corporation Cremorne, Australia
BioCardia Formerly VC-backed Sunnyvale, CA
Brainstorm Cell Therapeutics Corporation New York, NY
You’re viewing 5 of 9 competitors. Get the full list »

Longeveron Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Longeveron Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Longeveron‘s full profile, request access.

Request a free trial

Longeveron ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Longeveron’s complete esg history, request access »

Longeveron FAQs

  • When was Longeveron founded?

    Longeveron was founded in 2014.

  • Where is Longeveron headquartered?

    Longeveron is headquartered in Miami, FL.

  • What is the size of Longeveron?

    Longeveron has 38 total employees.

  • What industry is Longeveron in?

    Longeveron’s primary industry is Drug Discovery.

  • Is Longeveron a private or public company?

    Longeveron is a Public company.

  • What is Longeveron’s stock symbol?

    The ticker symbol for Longeveron is LGVN.

  • What is the current stock price of Longeveron?

    As of 20-Nov-2026 the stock price of Longeveron is $1.66.

  • What is the current market cap of Longeveron?

    The current market capitalization of Longeveron is $5.6M.

  • What is Longeveron’s current revenue?

    The trailing twelve month revenue for Longeveron is $1.17M.

  • Who are Longeveron’s competitors?

    Lisata Therapeutics, Coya Therapeutics, Cynata Therapeutics, BioCardia, and Brainstorm Cell Therapeutics are some of the 9 competitors of Longeveron.

  • What is Longeveron’s annual earnings per share (EPS)?

    Longeveron’s EPS for 12 months was -$7.95.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process